Father’s Day Sale: 15% off Sitewide w/code DAD15 (excludes sale items / ends Sun 6/21 at 9pm CST)
ANNIV40 for 40% OFF sitewide (no stacking, no sale items) ANNIV40 for 40% OFF sitewide (no stacking, no sale items) ANNIV40 for 40% OFF sitewide (no stacking, no sale items) ANNIV40 for 40% OFF sitewide (no stacking, no sale items) ANNIV40 for 40% OFF sitewide (no stacking, no sale items)

5-Amino-1MQ: What It Is and What the Research Tested

Updated 18 November 2026

5-amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), not a peptide. Its published record is cell and mouse work: five PubMed abstracts reviewed here name the compound, none testing it in people, and ClinicalTrials.gov listed no registered trials for it on 18 November 2026. A vial is judged by its lot certificate.

Renovita Research, a Missouri research supply company, lists it as 5 Amino 1-MQ 50mg (RESEARCH USE ONLY), with a lot certificate of analysis on the product page. Below: a paper-by-paper table of which compound each study names and what it measured, the salt detail that changes how amounts compare, and that certificate read line by line.

Key takeaways

  • 5-amino-1MQ is a quinolinium ion with no amino acids in it. Formula C10H11N2+ for the ion, C10H11IN2 for the iodide salt.
  • It blocks NNMT, the enzyme that methylates nicotinamide (vitamin B3) and produces 1-methylnicotinamide (1-MNA).
  • Many NNMT papers say “NNMT inhibitor” without naming the compound. Of the 15 papers below, five abstracts name 5-amino-1MQ, under four spellings and one salt name.
  • One Texas group wrote most of the unnamed-inhibitor papers and two of the five that name it. Labs in China, Italy and Turkey wrote the other three.
  • A vial is checked by its certificate: identity, purity, net content, water, acetate, metals, endotoxins, and what was not tested.

What is 5-amino-1MQ?

5-amino-1MQ is a methylquinolinium compound: a quinoline ring with a methyl group on the ring nitrogen and an amino group at position 5. That methylated nitrogen carries a permanent positive charge. So the molecule is an ion, and it is always made and sold with a counterion attached.

PubChem lists two forms:

FormPubChem CIDFormulaMolecular weightSource
5-amino-1MQ ion (1-methylquinolin-1-ium-5-amine)950107C10H11N2+159.21 g/molPubChem 950107
5-amino-1MQ iodide (the salt)66522933C10H11IN2286.11 g/molPubChem 66522933

The difference matters when you compare amounts. In the iodide salt, 159.21 of every 286.11 grams is the 5-amino-1MQ ion, about 56%. So 10 mg of the iodide holds about 5.6 mg of the ion. A paper that reports milligrams of the iodide and a vial labelled in milligrams of the ion are not describing the same quantity. At least one paper names the iodide outright: the 2024 bladder cancer study used “5-Amino-1-methylquinolinium iodide” (Yang et al. 2024).

5-amino-1MQ is often sold next to research peptides and often called one. It has no peptide bonds and no amino acids: ten carbon atoms, two nitrogens, one ring system.

What does an NNMT inhibitor do?

An NNMT inhibitor stops nicotinamide N-methyltransferase from adding a methyl group to nicotinamide. NNMT takes that methyl group from S-adenosylmethionine (SAM), and the product is 1-MNA. Nicotinamide is also a building block for NAD+, so blocking NNMT touches three things:

  • NAD+ supply: nicotinamide that NNMT methylates is no longer available to make NAD+.
  • Methyl supply: every reaction uses up one SAM, the cell’s main methyl donor.
  • 1-MNA output: the methylated product, which papers measure to show NNMT activity has dropped.
Diagram: an NNMT inhibitor sits in the NNMT enzyme, so nicotinamide is not methylated by SAM into 1-MNA and stays for NAD+

The case for NNMT as a target came before any 5-amino-1MQ paper. A 2014 study in Nature knocked down NNMT in mouse fat and liver, a gene-level change rather than a compound, and reported higher SAM and NAD+ in fat tissue and higher cellular energy expenditure (Kraus et al. 2014).

The chemistry came in 2017. A University of Texas team screened N-methylated quinolinium, isoquinolinium, pyridinium, benzimidazolium and benzothiazolium compounds. The quinoliniums blocked NNMT at about 1 μM (IC50, the concentration that halves the enzyme’s activity), and docking placed them in the enzyme’s nicotinamide-binding site (Neelakantan et al. 2017). 5-amino-1MQ is an N-methylated quinolinium, the scaffold that screen picked out.

What did the 5-amino-1MQ papers actually test?

The published work around 5-amino-1MQ is enzyme assays, cell studies, mouse studies and one review, and the abstracts do not all name the compound. Read each paper by what it names. “NNMTi” in an abstract means an NNMT inhibitor; on its own it does not say which one.

Year, journalCompound as the abstract names itModelWhat was measuredWatowich author / Ridgeline disclosureLink
2014, Naturenone (knockdown of NNMT)miceSAM, NAD+, energy expenditureno / noPMID 24717514
2017, J Med Chemquinolinium seriesenzyme assays, dockinginhibition strength (IC50 about 1 μM) and binding siteyes / noPMID 28548833
2018, Biochem Pharmacolmethylquinolinium analogues; “a potent NNMT inhibitor” in micemembrane assays, fat cells, diet-induced obese micepermeability, selectivity, 1-MNA, NAD+, SAM, body weight, fat massyes / noPMID 29155147
2019, Biochem Pharmacol“NNMTi”24-month-old mice after muscle injury; C2C12 cellsmuscle stem cell activity, fiber size, peak torqueyes / noPMID 30753815
2021, J Obstet Gynaecol“5MQ”, defined in the abstract as 5-amino-1-methylquinoliniumHeLa cervical cancer cellscell viability, gene and protein expressionno / noPMID 33645410
2021, Sci Rep“NNMTi”diet-induced obese mice on a diet switchbody composition, liver fat, fat-tissue metabolitesyes / yesPMID 33707534
2022, Sci Rep5-amino-1-methylquinoliniumdiet-induced obese mice on a diet switchgut microbiomeyes / yesPMID 35013352
2024, Sci Rep“NNMTi”aged mice, with and without exercisegrip strength, running, muscle fiber sizeyes / yesPMID 38969654
2024, Diabetes Obes Metab5A1MQdiet-induced obese mice, 28 daysbody composition, glucose, insulin, liver histology, blood and tissue levels of the compoundyes / yesPMID 39161060
2024, J Immunother Cancer5-Amino-1-methylquinolinium iodidebladder cancer mouse modelstumor growth alongside an anti-PD-L1 antibodyno / noPMID 39067875
2025, Biomolecules5-AMQ, tested with two other NNMT inhibitorsbone and skin cancer cell linesviability, reactive oxygen species, apoptosisno / noPMID 41301471
2025, Physiol Rep“NNMT inhibitor”mice with induced limb ischemiamuscle strength, power, perfusionno / noPMID 41108586
2025, Pharmacol ResAMO-NAM (a different inhibitor)aged female mice, heart failure modelheart function, 1-MNA in heart tissueno / noPMID 40484359
2026, Cell Rep“selective NNMT inhibition”kidney cells, organoids, micetubular senescence and fibrosisyes / yesPMID 41543936
2026, Trends Pharmacol SciNNMT inhibitors as a class (review)nonestate of inhibitor developmentno / noPMID 42067476

The five rows in bold are the abstracts that name 5-amino-1MQ: as 5-amino-1-methylquinolinium, 5A1MQ, 5MQ, 5-AMQ, or the iodide salt. Search all of those names when you look for papers, because no single name finds them all. The 2021 HeLa abstract shows how loose the naming is: it opens by calling 5MQ “5-methylquinolinium”, then defines 5MQ as 5-amino-1-methylquinolinium further down.

What the five papers that name the compound report:

  1. Obese mice, 28 days: the study reported that 5A1MQ limited gains in body weight and fat mass, improved glucose tolerance and insulin sensitivity, and reduced liver fat. The study also measured how much of the compound reached the blood, fat, muscle and liver (Babula et al. 2024).
  2. Obese mice on a diet switch: mice given the inhibitor with a low-fat diet developed a distinct gut microbiome pattern, with less Erysipelatoclostridium and more Lactobacillus than mice on the diet alone (Dimet-Wiley et al. 2022).
  3. Cancer models: in bladder cancer mouse models, the iodide salt reduced tumor growth and increased the tumor cell death seen with an anti-PD-L1 antibody (Yang et al. 2024). In cell lines, 5-AMQ and two other NNMT inhibitors lowered the viability of bone and skin cancer cells (Pompei et al. 2025) and 5MQ slowed HeLa cell growth without apparently affecting HEK-293 cells (Akar et al. 2021).

The other inhibitor papers describe a compound family or an unnamed “NNMTi”. The 2018 study, for example, found its methylquinolinium series lowered 1-MNA and raised NAD+ and SAM in cultured fat cells, and did not inhibit related SAM-dependent methyltransferases or the NAD+ salvage enzymes. Its mouse arm used “a potent NNMT inhibitor” it does not name (Neelakantan et al. 2018). The muscle papers (2019 and 2024 Sci Rep) do the same.

Two clues point to which compound those were. The 2022 microbiome paper, from the same group and with the same obese-mouse diet-switch design as the 2021 Sci Rep study, names its inhibitor as 5-amino-1-methylquinolinium. And the 2021 HeLa paper, from an outside group, writes that 5-amino-1-methylquinolinium “has shown promising results in the treatment of obesity and in senescent muscle regeneration”. Both suggest the earlier mouse work used it. The earlier abstracts themselves do not say so, so a page that credits their muscle or weight findings to 5-amino-1MQ is going a step past what those abstracts state.

Who ran the 5-amino-1MQ research?

The NNMT inhibitor work around 5-amino-1MQ comes mostly from one group. The papers that name the compound are more mixed.

  • One author on 8 of 15: S. J. Watowich (University of Texas Medical Branch, Galveston) is an author on the 2017, 2018, 2019, 2021 Sci Rep, 2022, both 2024 Sci Rep and Diabetes Obes Metab, and 2026 kidney papers.
  • One company on 5 of those 8: the 2021 Sci Rep, 2022, both 2024 papers and the 2026 Cell Reports paper disclose that Watowich founded Ridgeline Therapeutics, a Houston company, and that co-authors work or worked there. Each disclosure is printed under the abstract on PubMed.
  • Two of the five that name the compound: the 2022 microbiome study and the 2024 obese-mouse study come from that group.

The other three papers that name 5-amino-1MQ come from independent labs:

  • Sun Yat-sen University, Guangzhou, China (bladder cancer mouse models, 2024)
  • Polytechnic University of Marche, Italy, with Leiden University (cancer cell lines, 2025)
  • Selçuk University, Konya, Turkey, with partner universities (HeLa cells, 2021)

None of those three tested weight or obesity. Both obese-mouse studies that name 5-amino-1MQ come from the Watowich group.

Is there a clinical trial of 5-amino-1MQ?

No registered trial was found. A search of ClinicalTrials.gov for “5-amino-1MQ” on 18 November 2026 returned zero studies.

A 2026 review of NNMT inhibitors as a class, which does not single out 5-amino-1MQ, says “insufficient target engagement, reduced bioavailability, and unknown safety profiles have led to limited preclinical success across diseases”. It adds that newer drug-like inhibitors are being built to close those gaps (Puleo et al. 2026). Two of the review’s authors disclose a patent application on their own NNMT inhibitor.

The evidence on 5-amino-1MQ stops where the table stops: enzyme assays, cell lines and mice.

How do you read a 5-amino-1MQ certificate of analysis?

A certificate of analysis tells you what one tested lot contains. The label only tells you what the seller intends the vial to contain. The 5 Amino 1-MQ 50mg (RESEARCH USE ONLY) product page shows a certificate from an independent third-party lab. Here it is, line by line.

Certificate PMS-0689058792, lot VNS2609MQ50-RR-5AMB-0928, sample received 09/28/2026, report dated 09/29/2026:

LinePass mark printedResultWhat it tells you
Mass identification (LC-MS/MS)conforms to declared compound5-Amino-1MQ, passthe measured mass matches 5-amino-1MQ
Purity (HPLC)90.0% or more99.92%5-amino-1MQ’s share of the HPLC signal; the trace shows one peak, at 1.84 minutes
Net compound content90% of 50 mg or morepass, as an average of four vials weighedhow much compound is in the vial, as opposed to how clean it is
Water (Karl Fischer)10.0% or less5.93%moisture in the powder, part of the vial’s weight that is not the compound
Acetate (HPLC)under 12.0%4.01%acetate in the powder, measured separately from the compound
Heavy metals (ICP-MS)under 10 ppmnot detected
Bacterial endotoxins (LAL)under 5 EU/mgnot detected
Sterility (RMM)USP <71>not testedthe lot is not described as sterile
Mass balance95.0 to 105.0%conformsthe measured parts account for the whole, within the printed range

Three lines on any 5-amino-1MQ certificate deserve a second look:

  • The formula and weight it prints. This one prints C10H11N2 and 159.21 g/mol, the PubChem figures for the bare ion, with CAS number 685079-15-6. It names no salt form. So this certificate reports the compound as the bare ion, while at least one paper used the iodide salt. Check those lines against the salt table above before you compare an amount with a paper.
  • Net content, not purity alone. Purity says how clean the compound is; net content says how much of it is there. A certificate with only a purity figure answers half the question.
  • What was not tested. Sterility is marked “not tested”. A certificate covers only the tests it lists.

The sample details on the certificate describe the vial: orange lyophilized powder in a 3 ml glass vial with a blue cap and silver crimp seal.

Where to get 5-amino-1MQ with a lot certificate

Renovita Research lists 5 Amino 1-MQ 50mg (RESEARCH USE ONLY) with the certificate above on the product page, so a researcher can read the tested lot’s results before ordering. Other research compounds are in the Renovita peptide shop.

Renovita Research products are sold strictly for laboratory and research use only, not for human or animal consumption, and ship only to addresses within the United States.

Shopping Cart

Before You Enter

Renovita Research products are sold strictly for laboratory and research use only. Please confirm the following before continuing.

Scroll to Top